Search

DEA Extensions, eRX Fraud Prevention, HB25 Enacted

This notice from the Texas State Board of Pharmacy (TSBP) covers several key updates. It mentions the enactment of HB25, extensions related to the DEA, and measures for e-prescribing fraud prevention. The content appears to be a summary of recent regulatory and legislative changes relevant to pharmacy practice.

Professional Recovery Network, Fees and CE Updates

Professional Recovery Network, Fees and CE Updates

Rule, Disciplinary Action, & Remedial Plan Summaries

Rule, Disciplinary Action, & Remedial Plan Summaries

Texas Pharmacy and Medical Boards Joint Statement on Communication

The Texas Medical Board and Texas State Board of Pharmacy issued a joint statement reminding physicians and pharmacists of the importance of clear communication and collaboration in patient care. The statement emphasizes professional judgment and shared responsibility in ensuring safe and legitimate prescription practices.

WHO Handbook Accelerates Hepatitis Elimination Action

The World Health Organization (WHO) has released a new implementation handbook to support countries in accelerating action towards hepatitis elimination by 2030. The handbook consolidates evidence-based recommendations and provides practical guidance for expanding prevention, testing, and treatment services.

WHO Releases New Antibiotic Profiles for Drug-Resistant Infections

The World Health Organization (WHO) has released three new Target Product Profiles (TPPs) for antibacterial agents to address critical drug-resistant infections. These profiles guide the development of new antibiotics for multidrug-resistant Gram-negative infections, Gram-positive infections in vulnerable patients, and bacterial meningitis.

Teva Octreotide Recalled Due to Manufacturing Deficiencies

Health Canada has issued a Type I drug recall for Teva Octreotide due to manufacturing site deficiencies identified at a foreign facility. These deficiencies could lead to potential quality issues, including compromised sterility and dosing accuracy. The recall is a precautionary measure.

Health Canada Health Product InfoWatch - February 2026

Health Canada's February 2026 Health Product InfoWatch includes a monthly recap of safety information, including a recall of Teva Octreotide and advisories on unauthorized products. It also announces a consultation on controlling zuranolone and new market authorizations with conditions.

Health Canada Health Product Safety Recap

Health Canada has issued its February 2026 Health Product InfoWatch, detailing recalls for Teva Octreotide due to GMP deficiencies and unauthorized health products. It also announces a consultation on controlling zuranolone under the Controlled Drugs and Substances Act.

Japan PMDA Drug Precaution Revisions for FY2025

The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has published a list of drug precaution revisions for Fiscal Year 2025, detailing updates for various nonproprietary drug names. These revisions are effective on specific dates in late 2025 and early 2026, with associated investigation summaries available.